drug adverse effects of thiazolidinediones
Jump to navigation
Jump to search
Adverse effects
- New or worsening macular edema. Some cases improve after stopping or reducing glitazone.
- increased risk of heart failure (pioglitazone & rosiglitazone)
- increased risk of myocardial ischemia (rosiglitazone)
- decreased bone formation, accelerated bone loss, increased risk of fractures (wrist & hip)[4][5][11]
- increased risk of bladder cancer with long-term use (>= 5 years, RR=2.5 relative to sulfonylurea use)[9]
More general terms
References
- ↑ Prescriber's Letter 13(2): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220205&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Lincoff AM et al, Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes. JAMA 2007, 298:1180
- ↑ Lipscombe LL et al Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA. 2007 Dec 12;298(22):2634-43. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18073359
- ↑ 4.0 4.1 Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008 Apr 28;168(8):820-5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/18443256
- ↑ 5.0 5.1 Kahn SE et al, Rosiglitazone-associated fractures in type 2 diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18223031
- ↑ 6.0 6.1 Loke YK et al. Long-term use of thiazolidinediones and fractures in type 2 diabetes: A meta-analysis. CMAJ 2009 Jan 6; 180:32. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19073651
- ↑ 7.0 7.1 Habib ZA et al Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010 Feb; 95:592. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20061432
- ↑ 8.0 8.1 Bilik D et al. Thiazolidinediones and fractures: Evidence from Translating Research into Action for Diabetes. J Clin Endocrinol Metab 2010 Oct; 95:4560 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20631021
- ↑ 9.0 9.1 Mamtani R et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: A cohort study. J Natl Cancer Inst 2012 Sep 19; 104:1411 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22878886
- ↑ Kaul S, Bolger AF, Herrington D et al Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation. J Am Coll Cardiol. 2010 Apr 27;55(17):1885-94 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20413044
- ↑ 11.0 11.1 11.2 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
NEJM Knowledge+ Endocrinology
Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009 Jan 6;180(1):32-9. Epub 2008 Dec 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19073651 PMCID: PMC2612065 Free PMC article
Viscoli CM et al. Pioglitazone and risk for bone fracture: Safety data from a randomized clinical trial. J Clin Endocrinol Metab 2017 Mar; 102:914 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27935736 https://academic.oup.com/jcem/article-abstract/102/3/914/3061916/Pioglitazone-and-Risk-for-Bone-Fracture-Safety